Abstract
5122 Background: Five years survival of patients with advanced epithelial ovarian cancer (EOC) is 25–40% and once the disease recurs, treatment is mainly palliative. We evaluated whether continued treatment with carboplatin for an extended one-year period in women with complete response after platinum based combination, could prolong time to progression (TTP) and overall survival (OS). Methods: 14 patients were assigned to the protocol between 2/1996 to 6/2002 at the Oncology Division in Tel Aviv Sourasky Medical Center. Protocol schedule was: administration of Carbopltin at an AUC=6, three treatments every 2 months followed by two treatments once every three months (for a total of one year). All patients were previously treated with platinum based combinations and had achieved complete response (CR) by CT-scan and serum CA-125. Results: As of December 2003 with a median follow up of 42 months (range 18–93 months), the median TTP is 28 months (range 8–93+ months), and a median OS of 42 months (range 18–93+ months). Eight patients are still in complete remission and two more patients are still alive with disease. Conclusions: One year treatment (5 cycles) of single agent carboplatin that was administered to women with advanced EOC who achieved CR on platinum based chemotherapy as a first line, significantly prolonged TTP and OS compared to historical control. No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
